Jeffrey N Weiss1, Steven Levy2. 1. The Healing Institute, Margate, FL, USA. 2. MD Stem Cells, Westport, CT, USA.
Abstract
BACKGROUND: Usher syndrome is the most common form of syndromic retinitis pigmentosa and includes types I, II, and III with varying degrees of hearing loss. We present results of 10 eyes with Usher syndrome treated with autologous bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). METHODS: Preoperative Snellen visual acuities ranged from 20/30-1 to 20/400 with the average pre-operative Snellen acuity approximately 20/85 and the average logarithm of the minimum angle of resolution (LogMAR) acuity 0.635. All eyes had significantly impaired visual fields and patients reported hearing loss as part of this syndromic retinitis pigmentosa. Treatment using the protocols of the SCOTS study using BMSC provided by retrobulbar, subtenons, intravitreal and intravenous injections. RESULTS: Following treatment, 80% of the Usher eyes showed an improvement in visual acuity. Of the eyes that improved the average increase in visual acuity was 36.4% on LogMAR with improvements ranging from 23% to 94%. The average post-operative change in all treated eyes was a gain of 0.18 LogMAR and an increase in visual acuity of 28.3% on LogMAR. The results showed high statistical significance with P<0.001. Visual fields generally improved. No patient experienced a loss of vision. One patient underwent preoperative and 4-month post-operative audiometry testing which demonstrated improvement. The procedures were performed safely and without complications. CONCLUSIONS: Findings confirm meaningful improvement in visual acuity is possible in Usher syndrome using BMSC protocols developed in the SCOTS study. Statistical significance and safety were established. 2019 Stem Cell Investigation. All rights reserved.
BACKGROUND: Usher syndrome is the most common form of syndromic retinitis pigmentosa and includes types I, II, and III with varying degrees of hearing loss. We present results of 10 eyes with Usher syndrome treated with autologous bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). METHODS: Preoperative Snellen visual acuities ranged from 20/30-1 to 20/400 with the average pre-operative Snellen acuity approximately 20/85 and the average logarithm of the minimum angle of resolution (LogMAR) acuity 0.635. All eyes had significantly impaired visual fields and patients reported hearing loss as part of this syndromic retinitis pigmentosa. Treatment using the protocols of the SCOTS study using BMSC provided by retrobulbar, subtenons, intravitreal and intravenous injections. RESULTS: Following treatment, 80% of the Usher eyes showed an improvement in visual acuity. Of the eyes that improved the average increase in visual acuity was 36.4% on LogMAR with improvements ranging from 23% to 94%. The average post-operative change in all treated eyes was a gain of 0.18 LogMAR and an increase in visual acuity of 28.3% on LogMAR. The results showed high statistical significance with P<0.001. Visual fields generally improved. No patient experienced a loss of vision. One patient underwent preoperative and 4-month post-operative audiometry testing which demonstrated improvement. The procedures were performed safely and without complications. CONCLUSIONS: Findings confirm meaningful improvement in visual acuity is possible in Usher syndrome using BMSC protocols developed in the SCOTS study. Statistical significance and safety were established. 2019 Stem Cell Investigation. All rights reserved.
Entities:
Keywords:
Usher syndrome; bone marrow derived stem cells (BMSCs); retinitis pigmentosa (RP); syndromic retinitis pigmentosa; visual loss
Authors: L Kordelas; V Rebmann; A-K Ludwig; S Radtke; J Ruesing; T R Doeppner; M Epple; P A Horn; D W Beelen; B Giebel Journal: Leukemia Date: 2014-04 Impact factor: 11.528
Authors: Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Ann Moser; Robert J Brockhurst; K C Hayes; Chris A Johnson; Ellen J Anderson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer Journal: Arch Ophthalmol Date: 2004-09
Authors: J Sancho-Pelluz; M V Alavi; A Sahaboglu; S Kustermann; P Farinelli; S Azadi; T van Veen; F J Romero; F Paquet-Durand; P Ekström Journal: Cell Death Dis Date: 2010 Impact factor: 8.469
Authors: Marta P Wiącek; Wojciech Gosławski; Aleksandra Grabowicz; Anna Sobuś; Miłosz P Kawa; Bartłomiej Baumert; Edyta Paczkowska; Sławomir Milczarek; Bogumiła Osękowska; Krzysztof Safranow; Alicja Zawiślak; Wojciech Lubiński; Bogusław Machaliński; Anna Machalińska Journal: Stem Cells Int Date: 2021-06-02 Impact factor: 5.443